Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will admit to caring about this company and its technological capabilities for the better part of thirty years. I had nothing to do, however, with effecting a management change. What I did, twenty months ago, was become proactive with minority shareholders. Our Board moderators are to be thanked for allowing me to bend the rules just a little bit to post "Go To Meeting" numbers and codes so that shareholders could have an audio forum in which to convene. The result, between the calls and the subsequent emails, was a pledge of shares in excess of the minimum needed to demand the convening of a special shareholder meeting had we not been able to meet in Salt Lake City last December. The new CEO, at that time, was informed of our meetings and their results. I personally believe WhatIsValue should be on the Medizone Board of Directors. His detailed analysis of many of our issues has been "spot-on".
This sympathy move down with Amgen will pass over time....hopefully a short time.
Kudos, BenK, for your work on our cover pages. A decade of "incorrect" (at best) information finally has been deleted from our cyber space. New users now can assess where the company stands on the marketing and regulatory fronts. The improved professionalism of our written word compliments the improved professionalism of our management team. It's all good!
Thanks for the clarification. Still......Medizone needs to get after it.......NOW.
The CE stamp tells us that Medizone has absolutely no government obstacles to selling Asepticsure in Europe. That same CE stamp, in my humble pea brain, then tells me that it encompasses everything our EPA/FDA could represent. Five years ago, IMHO, an EPA approval and/or a CE stamp would have had this stock trading above a dollar per share before everyone reminded themselves that there was no infrastructure to support a marketing program. The only excuse the company has today to not sell Asepticsure is the fact that there is still no marketing program. Maybe the company was blindsided with this great news. Whatever the circumstances, Medizone needs marketing partners or a final sale of the company. It's now or never.
Every concern brought forth by shareholders relates back to the lack of testing following the Belleville outbreak. No one can get an FDA approval without rounds of testing. I remain surprised at the EPA approval given the amount of overall real-life testing that was done. The company needs test sites.....NOW.
I bet Esposito and the Board scrutinized Dodd's laundry and found it to be more hype than substance.
Let's keep in mind that Medizone now has its first full time CEO in many years. The company needs a full time CEO now more than ever. Few CEOs of publicly traded companies, especially in biotech and related industries, have had totally smooth sailing throughout their careers. Keep in mind that the previous employer was Canadian. That firm had failed tests, and maybe Dodd was really trying to rescue the product. Who knows? All I know is that we heard a former CEO of Serologicals tells shareholders that he is going to go to work every day and get AS on the market.
No one hates Aurinia, YOU, or your posts. That being said, you are responsible for 25% of the last 64 posts. Many posts are quite redundant. We're not a dementia laden group and can retain a portion of what we read.
Thanks, Go. Having waded through Elena, Erin, Opal, Ivan, and Dennis over the years, I do realize how devastating Irma is. Should the direction of this storm shift to the Gulf coast, I probably will head inland for the first time.
One difference between Armune and Medizone stuck out like a sore thumb: testing
Reverse splits versus regular splits
Penny stocks have dropped for decades when news is elusive. Everyone knows you're short, and we have pointed out risks related to the greed of trying to get the last dime. Trying to talk us into cheering the final downside with you will be difficult for people who have followed this company for several years. You obviously made a good shorting decision some months ago. Your greed slip, however, continues to show.
The billion authorized shares are immaterial at this point. The company has been redeeming shares, not issuing shares.
This whole scenario goes back to the lack of real-life tests five years ago. Nothing significant took place after the Belleville success of 2013 (or before it either). The company should have had clear sailing the minute the EPA conceded. The Belleville stats were huge, and they easily blew every competitor out of the water, but, alas, there should have been a dozen more similar tests for proof.
New financing would redeem the convertible note and the rest of the high priced debt. The conversion rate would not have been favorable anyway at this price. I am looking for upside here.
You're grasping at straws trying to make the last 6-8 cents. There is no room for another reverse split. What if the new financing erases all previous toxic debt? A little bit of extra dilution is meaningless at this point and can become a positive addition especially if the toxic debt is wiped out. Don't forget about the developing world. The need for this system is huge.
Your greed slip is showing. Should the company announce the beginning of a relationship with China (they are trying) and/or a positive response about dialogue with the FDA, you're going to wish you didn't try to go after the last eight cents.
So far, the stock has survived a 2nd attempt to push it below the $6.00 support level. Each time that event occurs, the $6.00 support area will become stronger.
There is neither reason nor room for another reverse split. You're risking your entire profit on the last 8-10 cents.
An observation: You could close out your short position, pat yourself on the back for a job well done, and not even worry about the last 8-10 cents. They will be the toughest.
Are you kidding us, cervelo? Since when does a fledgling biotech stock mirror the S&P 500? The company has neither earnings nor sales, and you're blaming the Cramer show for its junk bond status? AUPH, like any biotech stock without a marketable product, is lucky to get outside financing at all.
If the company had another reverse split, there wouldn't be a float.
Understood and in agreement. The FDA has turned the company down three times. Cartwright thinks they have it figured out this time. His two week old press releases are the first non-earnings related new stories the company has produced in several months. He is letting the world know that he hasn't given up. He is carrying the brunt of the responsibility for, what was previously, a very inept organization when it came to heeding the advice of the reviewers at the FDA.
The company had a press release a couple of weeks ago saying it had re-engaged the FDA concerning its US NDA and would be re-submitting it once funding arrived.
Continuous angst and hand wringing compromise the credibility of this normally informative board. We all know the P3 process is going to be a lengthy ordeal. Whether or not the big V gets pulled mid-stream and taken to the FDA or waits out the entire P3 process is beyond all of our pay grades. The "What Ifs" are many and varied in scope. I am relaxing and allowing the chips to fall where they may fall.
CJAKE........when there is a float as small as GTHP, with very little trading going on compared to prior years, then one has to expect the spread to widen. The market makers are trying to make some money and keep an orderly market at the same time.....which is a bit tough to do with a tiny float like GTHP has.
So you are short! I don't take orders from you, and business is being attempted in China.
Oh Yes it is.
GTHP may be undervalued if the Chinese go after it full blast and if financing comes in to re-address the FDA....for the 4th time. If "none of the above" takes place, then all we can do is wonder what number the protected technology would be sold to the highest bidder. One would have to wonder if a bidding process would even be contemplated in the U.S. with Merck already having a cervical cancer vaccine on the market.
The stock, supposedly on no one's radar, went from 16 cents to 9 cents fairly quickly. My guess would be there is negative news out there that has been disseminated to only a select few. This company has little wiggle room. It needs a financing arm to come through to enable it to have funds to readdress the FDA. It's over if Cartwright can't secure funding in the next six months.
No worries, awlau. Glickman covered everyone's butt no matter who among Cramer's dwindling audiences happened to tune in that day. It would be interesting to know his average audience demographics. Personally, I can't imagine too many unsophisticated investors bothering with him.
It's pretty apparent that you're short while others are long. There wouldn't be any reason for you to jump on a long's case if you weren't short.
See, YDN74? You try to manipulate people as well.
The whole world knows that AUPH is speculative, whether or not it was blurted out on CNBC. I imagine Mr. Glickman was just providing a little additional CYA to the firm and to CNBC.
All that headline means is that, if approved, the product will receive the same seven year exclusive rights status that AUPH received. No big deal. AUPH is much closer to fruition than any competitors.
Let's see: The company has no revenues and none are expected for three years. The company has no earnings and none are expected for four years. The company is trying to work within the biotech industry, an industry group where companies fail on a monthly basis. Gee....I think what we have here describes a Blue Chip stock! Last night's performance was a textbook "buy on the rumor" and "sell on the no news" scenario. What type of promises were people actually expecting last night from the primary enrollment of a Phase III trial? Glickman didn't need to announce that AUPH is a speculative stock.....the world already knew it......so that's NOT why the stock dropped this morning.
.....as do you.
The amount of daily repetitive gibberish is becoming a risk to this board.
The stock did not drop overnight from 11 to 6. It was methodical. Some institutions and individuals were buying on the way down while other institutions and individuals were selling on the way down. So far, the net selling seems to have dried up around the $6.00 mark. Sure, other people who bought in the $1.00 to $2.00 range can be expected to do some selling in the $6.00 area as well. Not every shareholder has an emotional attachment to AUPH. It's strictly a business transaction. We're in for a long ride on Phase 3, so it's best that shareholders just relax and see how it all plays out.